From Yahoo Finance: 2025-05-11 17:16:00

President Trump’s healthcare-focused executive order aims to allow Medicare to negotiate prescription drug prices, a move supported by the pharmaceutical industry. Drug makers seek to delay price negotiations for small-molecule drugs by four years. Trump’s order also aims to cut healthcare costs and may precede sector-specific tariffs.

The controversial topic of Medicare’s negotiating powers has led to a debate on how drug prices should be regulated. White House officials suggest upcoming changes in negotiation processes will yield significant savings. Under the Biden administration, price cuts were achieved for various medications, including Pfizer and Novo Nordisk’s popular treatments.

Option Care Health, Inc. (OPCH) provides infusion therapy and healthcare services through a network of pharmacies. Analysts have upgraded OPCH to a Buy rating, citing strategic positioning and strong financial performance. The company’s integration of STELARA is expected to support growth amid the industry’s shift towards home care, leading to potential acquisitions and tariff management.

OPCH ranks 9th among the best performing healthcare stocks to buy now. While it shows promise for investment, some AI stocks may offer higher returns within a shorter timeframe. Investors seeking AI opportunities can explore a report on the cheapest AI stock with significant upside potential, offering a unique investment opportunity in the evolving market.

Read more: Is Option Care Health (OPCH) the Best Performing Healthcare Stock to Buy Now?